• LAST PRICE
    3.0300
  • TODAY'S CHANGE (%)
    Trending Up0.0100 (0.3311%)
  • Bid / Lots
    3.0200/ 8
  • Ask / Lots
    3.0500/ 3
  • Open / Previous Close
    2.9700 / 3.0200
  • Day Range
    Low 2.9500
    High 3.0500
  • 52 Week Range
    Low 0.3599
    High 6.0400
  • Volume
    117,250
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 3.02
TimeVolumeADCT
09:32 ET38622.95
09:33 ET16623
09:35 ET67303.01
09:37 ET16912.97
09:39 ET4002.98
09:42 ET2642.99
09:44 ET3002.99
09:46 ET62823.02
09:48 ET11682.99
09:50 ET3002.99
09:51 ET9823
09:53 ET2003
09:55 ET6643
09:57 ET7142.99
10:00 ET18833
10:02 ET23942.975
10:04 ET12852.99
10:06 ET317083.01
10:08 ET8003.03
10:09 ET8303.0112
10:11 ET2303.015
10:13 ET6003
10:20 ET6022.99
10:22 ET72853.02
10:24 ET4003.01
10:26 ET3003
10:27 ET1002.995
10:36 ET81052.97
10:38 ET12652.98
10:40 ET2002.98
10:42 ET1002.99
10:44 ET22043.02
10:45 ET4003.02
10:47 ET4783.04
10:51 ET48763.05
10:54 ET8503.04
10:58 ET1003.04
11:00 ET119683.02
11:02 ET23173
11:03 ET2003.01
11:05 ET30823.02
11:09 ET2003.03
11:12 ET4253.03
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesADCT
ADC Therapeutics SA
292.0M
-1.2x
---
United StatesPSNL
Personalis Inc
283.5M
-3.3x
---
United StatesCDXS
Codexis Inc
247.5M
-4.1x
---
United StatesFATE
Fate Therapeutics Inc
314.3M
-1.5x
---
United StatesPSTX
Poseida Therapeutics Inc
245.7M
-2.2x
---
United StatesEDIT
Editas Medicine Inc
237.5M
-1.2x
---
As of 2024-11-05

Company Information

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Contact Information

Headquarters
Biopole, route de la Corniche 3BEPALINGES, Switzerland 1066
Phone
---
Fax
---

Executives

Non-Executive Chairman of the Board
Ron Squarer
Chief Executive Officer, Director
Ameet Mallik
Chief Financial Officer
Jose Carmona
Chief Scientific Officer
Patrick Van Berkel
Chief Legal Officer
Peter Graham

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$292.0M
Revenue (TTM)
$66.7M
Shares Outstanding
96.7M
ADC Therapeutics SA does not pay a dividend.
Beta
1.59
EPS
$-2.55
Book Value
$-1.80
P/E Ratio
-1.2x
Price/Sales (TTM)
4.4
Price/Cash Flow (TTM)
---
Operating Margin
-206.87%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.